Purpose: To investigate the influences of metformin on the proliferation and apoptosis of mouse melanoma B16 cells through regulating the phosphatidylinositol 3-hydroxy kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway.

Methods: The mouse melanoma B16 cell strains were taken as the subjects of the study, and were randomly divided into the control group with RPMI-640 medium with the volume same with that in the metformin group (C group, n=6) and Q group [metformin:10 mmol/L (Q1 group, n=6), metformin:20 mmol/L (Q2 group, n=6), and metformin:40 mmol/L (Q3 group, n=6)]. The cell counting kit-8 (CCK-8) method was employed to detect the proliferation of cells in each group at different culture times. The apoptosis of cells in each group was detected via flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL).

Results: The proliferation rate in Q group was lower than in C group, and the difference was statistically significant (p<0.05 or p<0.01). According to the results of flow cytometry, it was concluded that the number of apoptotic cells in Q group was higher than in C group (p<0.05 or p<0.01). TUNEL results revealed that compared with that in C group, the apoptosis rate in Q group was increased (p<0.05 or p<0.01). Moreover, western blotting results showed that the protein expression levels of PI3K, Akt and mTOR in Q group were higher than in C group.

Conclusions: Metformin can inhibit the proliferation of mouse melanoma B16 cells and induce their apoptosis probably through its regulation on the PI3K/AKT/mTOR signaling pathway in cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

melanoma b16
12
group n=6
12
mmol/l group
12
group
11
b16 cells
8
mouse melanoma
8
cells group
8
metformin induces
4
induces apoptosis
4
apoptosis melanoma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!